Sensius: “Hyperthermia for H&N can be introduced without additional cost”
Amersfoort, 27 june 2016 - At a special event of KWF Kankerbestrijding (DCI) on Business Models for the Future, Sensius presented its case to improve quality of life and life expectancy for patients with Head&Neck Cancer.
Studies have revealed the significant improvement that can be achieved through the addition of hyperthermia to the current standard treatment. At this moment, 40% of all treatment costs are devoted to treatment of recurrence after primary treatment. Addition of hyperthermia to the primary treatment will cut this component in half. Savings in total treatment cost outweight the additional costs of hyperthermia in the primary treatment.
“Addition of hyperthermia to the primary treatment will be highly beneficial for the patient, without adding cost to the total health care system”, says Paul van den Biggelaar, CEO of Sensius. The impact of H&N cancer is significant for patients. As soon as thermal therapy is added to the standard treatment of H&N cancers, patients will have a much better perspective to quality of life and a higher life expectancy.
The poster can be downloaded, see above at your right side 'Download documents'.